Trials / Completed
CompletedNCT00633893
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
A Safety and Efficacy Trial Evaluating the Use of Apixaban for the Extended Treatment of Deep Vein Thrombosis and Pulmonary Embolism
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,711 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apixaban | Tablets, Oral, twice daily, 12 months |
| DRUG | Placebo | Tablets, Oral, twice daily, 12 months |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2012-08-01
- Completion
- 2012-08-01
- First posted
- 2008-03-12
- Last updated
- 2013-11-25
- Results posted
- 2013-10-25
Locations
428 sites across 29 countries: United States, Argentina, Australia, Austria, Brazil, Canada, Chile, Czechia, Denmark, France, Germany, Hong Kong, India, Israel, Italy, Mexico, Norway, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Singapore, South Africa, South Korea, Spain, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00633893. Inclusion in this directory is not an endorsement.